FDA Guides Drug Makers to Faster Generic Copies
Published Date: 2/27/2026
Notice
Summary
The FDA just released new draft guides to help drug makers design tests proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by April 28, 2026, before these guides become official. These updates aim to speed up drug approvals, saving time and money for everyone.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Posts Draft BE Study Guidances
The FDA posted new draft and revised draft product-specific guidances that give recommendations for designing bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). The notice lists many active ingredients covered (for example: apixaban, buprenorphine, semaglutide, tadalafil, acetaminophen, and others) and the FDA is accepting comments on these drafts through April 28, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-03961, Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for Comments
The FDA is hosting a fun and important workshop on June 8-9, 2026, to talk about new science and research for generic drugs. They want input from drug makers, scientists, patients, and anyone interested to help shape next year’s plans. If you want to share your thoughts, make sure to send comments by July 10, 2026—this helps improve affordable medicine for everyone!
Next: 2026-03964, Intertek Testing Services NA, Inc.: Application for Expansion of Recognition
Intertek Testing Services NA, Inc. wants to expand its role as a trusted safety tester recognized by OSHA. This means they can test more products to make sure they’re safe for workers and the public. If you have thoughts or info, you’ve got until March 16, 2026, to speak up—this could speed up safety checks and impact businesses relying on testing.